Toshio Kubo
Okayama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 117 publications
Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 23, 2026
ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 16, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.
Journal: JAMA network open
Published: November 12, 2025
Correction: Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up.
Journal: Cureus
Published: October 20, 2025
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 11, 2025
Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up.
Journal: Cureus
Published: February 14, 2025
Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022.
Journal: International journal of clinical oncology
Published: January 17, 2025
Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors.
Journal: International journal of clinical oncology
Published: December 26, 2024
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.
Journal: International journal of clinical oncology
Published: December 17, 2024
Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Journal: Scientific reports
Published: October 25, 2024
Last Updated: 09/26/2026